Biochemical and Biophysical Research Communications
Volume 105, Issue 3, 14 April 1982, Pages 1090-1095
Selective inhibition of platelet lipoxygenase by baicalein
References (10)
Biochim. Biophys. Acta
(1977)- et al.
J. Biol. Chem
(1980) - et al.
J. Biol. Chem
(1978) - et al.
- et al.
There are more references available in the full text version of this article.
Cited by (250)
A comprehensive investigation on the interaction between jaceosidin, baicalein and lipoxygenase: Multi-spectroscopic analysis and computational study
2024, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyBiology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk
2022, Biochemical PharmacologyParalog- and ortholog-specificity of inhibitors of human and mouse lipoxygenase-isoforms
2022, Biomedicine and PharmacotherapyThe main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review
2021, Biomedicine and PharmacotherapyCitation Excerpt :Similarly, oroxylin A has been shown to inhibit COX-2 expression and reduce the synthesis of PGE2 in LPS-induced macrophages [78,79]. Furthermore, baicalin can selectively inhibit the activity of platelet LOX [184] and 5-LOX and reduce production of the 5-LOX metabolite LT [185,186]. Baicalin has also been shown to inhibit the expression of COX-2 in rats with brain injury [187,188], and found to have significant anti-depressant activity in mice with mild chronic stress by inhibiting COX-2 expression and activity and reducing PGE2 levels in the frontal cortex and hippocampus [189].
Modulation of regulatory T cells by natural products in cancer
2019, Cancer Letters
Copyright © 1982 Published by Elsevier Inc.